United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold

UNITED THERAPEUTICS Corp

Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.
Bylaw amendments: create cure process for shareholder nomination deficiencies; lower shareholder vote to amend bylaws from 80% to majority.
Tracey is President/CEO of Feinstein Institutes, co-founder of SetPoint Medical; brings expertise in inflammation and bioelectronic medicine.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

UNITED THERAPEUTICS Corp: Amended and restated bylaws to implement cure process for director nomination deficiencies, remove language allowing board to require supermajority vote, and lower stockholder vote required to amend bylaws from 80% to majority of voting power (effective 2026-01-21).

Change: bylaw amendment
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, the Board also approved amendments to, and the restatement of, the Company’s Tenth Amended and Restated Bylaws.

View on SEC.gov

Browse all governance changes →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-005810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.